Abbott Laboratories

New York Stock Exchange
Back to all articles
Somewhat Bullish +45

Abbott Laboratories $ABT Stock Holdings Lessened by BI Asset Management ...

AI-generated analysis

📉 BI Asset Management reduced its Abbott Laboratories stake by 20.0% in Q1, selling 17,693 shares to hold a remaining position valued at $7.27 million.

📈 J. Stern & Co. LLP dramatically increased its position by 12,439.6% in Q4, acquiring over 39 million shares worth nearly $4.93 billion.

🏦 Vanguard Group boosted its holdings by 1.4% in Q4, now owning 175.56 million shares valued at approximately $22 billion.

💰 Abbott Laboratories reported Q1 revenue of $11.16 billion, beating analyst estimates of $10.99 billion and growing 7.8% year-over-year.

📊 The company posted earnings per share of $1.15, surpassing the consensus estimate of $1.14 with a net margin of 13.90%.

🎯 Management issued FY 2026 EPS guidance ranging from $5.38 to $5.58, slightly below the analyst consensus forecast of $5.48.

💵 A quarterly dividend of $0.63 per share is scheduled for payment on August 17th to shareholders of record on July 15th.

📉 Analyst price targets were lowered by UBS ($158 to $135), Wells Fargo ($122 to $109), and Stifel ($145 to $120) in recent reports.

👔 CFO Philip Boudreau purchased 2,200 shares at an average price of $91.50, while Director Daniel Starks bought 10,000 shares at $92.65.

📈 The stock maintains a consensus rating of 'Moderate Buy' with a MarketBeat consensus price target of $118.30.

Bullish Signals
  • Abbott Laboratories beat Q1 earnings expectations with EPS of $1.15 versus the consensus of $1.14.
  • Revenue reached $11.16 billion, representing a solid 7.8% increase compared to the same quarter last year.
  • Major institutional investors including Vanguard Group and Norges Bank increased their stakes in the company during the reporting period.
  • The company maintains a healthy dividend yield of 2.8% with an annualized payout of $2.52 per share.
  • CFO Philip Boudreau and Director Daniel Starks executed open market purchases, signaling insider confidence in the stock's valuation.
Risk Factors
  • Several major analysts recently lowered their price targets, including UBS dropping to $135 and Wells Fargo reducing its objective to $109.
  • Daiwa Securities Group downgraded the stock from an 'outperform' rating to a 'neutral' rating in late April.
  • The consensus analyst price target of $118.30 is below the current trading price implied by recent insider purchase prices of over $91.
Full Analysis
Abbott Laboratories (NYSE:ABT) saw mixed institutional activity in the first quarter, with BI Asset Management reducing its stake by 20% to 70,805 shares. Conversely, major funds like J. Stern & Co., Norges Bank, Invesco Ltd., and Vanguard Group increased their holdings significantly, with Vanguard boosting its position to over 175 million shares worth approximately $22 billion. Financially, Abbott reported strong Q1 results on April 16th, posting $1.15 EPS against a consensus of $1.14 and revenue of $11.16 billion, which beat estimates of $10.99 billion. The company achieved a 7.8% year-over-year revenue increase, maintaining a net margin of 13.90% and a return on equity of 17.62%. Management provided FY 2026 EPS guidance between $5.38 and $5.58. Analyst sentiment remains cautiously positive despite some price target reductions from firms like UBS and Wells Fargo, which lowered targets to $135 and $109 respectively while maintaining buy or overweight ratings. The stock offers a 2.8% dividend yield with an upcoming payment of $0.63 per share to shareholders of record on July 15th. Insider trading activity includes CFO Philip Boudreau purchasing 2,200 shares at $91.50 and Director Daniel Starks acquiring 10,000 shares at $92.65, indicating continued confidence from company leadership. Institutional ownership stands at 75.18%, with insiders holding an additional 0.46% of the outstanding stock.